Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274458 | 0.89 | DRD2 (0.35) | DRD2DRD3OPRM1OPRK1SIGMAR1 | |
| SCHEMBL276375 | 0.80 | SIGMAR1 (0.34) | DRD2DRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL9609548 | 0.79 | POLB (0.51) | POLB | |
| SCHEMBL274872 | 0.78 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL552965 | 0.77 | DRD3 (0.71) | DRD2DRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL6521499 | 0.76 | POLB (0.47) | POLB | |
| Hydrochloric Acid SCHEMBL28327056 | 0.75 | DRD3 (0.69) | DRD2DRD3OPRM1OPRD1OPRK1 | |
| SCHEMBL3936524 | 0.75 | MAPT (0.38) | POLB | |
| SCHEMBL1376734 | 0.74 | AOC3 (0.36) | DRD3OPRM1SIGMAR1DRD1 | |
| SCHEMBL7327745 | 0.73 | DRD2 (0.61) | DRD2DRD3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4819280-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | claimed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | claimed |
| JP-2004500426-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | claimed |
| EP-1274411-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | Axon Biochemicals B.V. (NL) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078713-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | AXON BIOCHEMICALS B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| EP-1274411-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | Axon Biochemicals B.V. (NL) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078713-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | AXON BIOCHEMICALS B.V. (NL) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885OPRM1 107/4885 |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | DRD2 9/4885DRD3 18/4885OPRM1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.